(NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more ...

Discover emerging therapies for hyperkalaemia to enhance chronic kidney disease and heart failure management on World Kidney Day.

The approval follows PEGASUS Phase III trial assessing Palynziq efficacy and safety compared to diet alone in adolescents ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 2:00 PM EDTCompany ParticipantsAdam Steensberg - President ...

Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to ...

Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS ...

Science is a subject built on doing. Students learn chemistry through titrations, biology through dissections, physics through motion experiments, and earth science through field observations. That ...

The stock market is often dismissed as risky or overly complex, but in reality, it rewards disciplined analysis more than ...

Hello, and welcome to the presentation of ALK's Q4 and full-year 2025 results. My name is Per Plotnikof. I'm Head of Investor Relations, and thank you all for joining. On slide 2, I will present the ...

Guideline-directed medical therapy and dose titration are essential to improving outcomes in heart failure with reduced or mildly reduced ejection fraction.According to the CDC, 6.7 million U.S.